Biohaven Ltd. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Biohaven Ltd. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($738.82M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($846.42M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($408.17M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($570.28M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($213.80M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($118.67M) | Mar 23, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($745.38M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($885.11M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($436.05M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($567.93M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($218.90M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($114.51M) | Mar 23, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $635.07M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $795.87M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $373.28M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $437.07M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $181.49M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $98.46M | Mar 23, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($609.44M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($582.45M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($331.73M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($297.69M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($145.84M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($75.96M) | Mar 23, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $715.0K | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $4.05M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $3.05M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $6.07M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $938.0K | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.10M | Mar 23, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $451.45M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $615.11M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $513.21M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $661.78M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $142.06M | Mar 23, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $399.38M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $191.67M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $85.24M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $123.01M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $47.37M | Mar 23, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.07M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $423.44M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $427.98M | Mar 2, 2026 |
| FY2025 | Dec 31, 2022 | $538.77M | Mar 2, 2026 |
| FY2024 | Dec 31, 2021 | $34.69M | Mar 3, 2025 |
| FY2023 | Dec 31, 2020 | $16.78M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $14.45M | Mar 23, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.39M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.39M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $1.39M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $1.39M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.39M | Mar 23, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.08B) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($1.35B) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($499.29M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($91.12M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 23, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $229.96M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $99.13M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $248.40M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $204.88M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $76.06M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $82.51M | Mar 23, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (9) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | (5) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | (12) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | (5) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Mar 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (9) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | (5) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | (12) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | (5) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Mar 23, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 132.78M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 101.22M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 81.12M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 68.19M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 23, 2023 |